Compare Bank Multiarta Sentosa Tbk. (MASB) vs Organon Pharma Indonesia Tbk. (SCPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank Multiarta Sentosa Tbk. vs Organon Pharma Indonesia Tbk. — how do they compare? Bank Multiarta Sentosa Tbk. trades at Rp3,360 (market cap 4.7T, 10K 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Bank Multiarta Sentosa Tbk. is far larger — about 45× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| MASB | SCPI | |
|---|---|---|
Market Cap | 4.7T | 104.4B |
Volume | 10K | — |
Lot | 100 | — |
Turnover | 33.47M | — |
Average Price | 3,347 | — |
Value | 33.47M | — |
Indicative Equilibrium Price | 3,230 | — |
Indicative Equilibrium Volume | 10 | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bank Multiarta Sentosa Tbk.
PT Bank Multiarta Sentosa Tbk (the Bank) was established by Deed No.201 dated July 28, 1992 of H.Saidus Sjahar, S.H. The Bank's parent company is PT Danabina Sentana which is the majority stockholder of the Bank. The majority shareholder of PT Danabina Sentana is PT Lumbung Artakencana which is a company established in Indonesia and the Bank’s ultimate shareholder that joined in business group of Wings Group.
Read more on MASB →About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →
